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Abstract
This paper considers the impact of foreign aid for HIV on the number of new infections in
low middle income countries . We provide causal estimates by improving on earlier studies by
addressing the endogeneity of aid disbursements through the use of instrumental variables. In
addition, we effectively control for unobserved country specific effects that might jointly influence
aid allocation and new infections in a country. We provide evidence on the effectiveness of foreign
aid in reducing new infections of HIV across age groups, as well as separately amongst adults
and children. We find a statistically significant and important negative effect of foreign aid on
the number of new infections for our overall measure - across age groups and amongst adults. We
find no statistically significant evidence amongst children across low middle income countries,
but find evidence of strong differential effects in sub-Saharan Africa.
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1 Introduction
Since the beginning of the Human Immunodeficiency Virus (HIV) epidemic in the 1980s nearly
30 million people have died from acquired immune deficiency syndrome (AIDS) and related diseases.
As of 2012 there were around 35 million people living with HIV, and each year a further 2.5 million
individuals become infected. The disease burden has been most severe in sub-Saharan Africa (SSA)
where in some countries almost one in five people is infected with HIV. Despite the magnitude and
severity of the epidemic significant progress has been made since the late 1990s when HIV came
into the focus of the international development community. New infections have fallen across all
age groups by 38% since 2001 and rapid scale-up of access to treatment has been possible.
The response of the international donor community to the epidemic has seen extraordinary
amounts of funds channeled to prevention and treatment of HIV. In 2013 funding reached its peak
with an estimated US$19.1 billion being committed to programs in low and middle income countries.
Despite these vast amounts of resources the end of the epidemic is still not in sight and there
remains a large financing gap in the amount needed to reach the 2015 targets of universal access
to prevention, treatment and care for HIV worldwide. Schwartlander et al. (2011) have developed
an investment framework for 139 low-middle income countries and estimate around US$22 billion
being needed by 2015. On the other hand, there have been questions raised about whether foreign
aid for HIV has been displacing funding for other important health concerns Shiffman (2008). For
example between 1998 and 2007 funding for HIV control grew from 5.5% to almost 50% of all aid
given for health (Shiffman, Berlan and Hafner, 2009). The same study finds that in contrast, during
the same time period the amount of aid given to reproductive health declined by almost half. While
reducing the impact of the epidemic on health is in its own right important, the epidemic has also led
to negative consequences on the socio-economic environment of affected countries. Several studies
have examined the economic and human capital consequences of the epidemic. Fortson (2011) finds
that in sub-Saharan Africa areas with higher levels of HIV had larger reductions in schooling. In a
paper studying the labor market effects of the epidemic in South Africa Chicoine (2012) finds that
AIDS mortality led to reductions in employment in Africa and reduced wages amongst Black South
Africans. But the importance and benefits of treatment and access to care is clearly highlighted
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in a study by Thirumurthy, Graff Zivin and Goldstein (2008) who find six months after treatment
initiation the probability of labor force participation amongst HIV positive individuals increased by
20 percent in Western Kenya. These statistics and studies highlight the importance of controlling
the HIV epidemic but equally they highlight the importance of understanding the returns to the
massive investments made. Our study is aimed at addressing this question with a specific focus on
the reductions in the number of new infections of HIV.
There have been a few studies that have analyzed the direct relationship between foreign aid
flows for HIV and health outcomes. The most comprehensive of these Bendavid et al. (2012) uses
data from Demographic and Health Surveys in 27 sub-Saharan African countries to investigate the
impact of the President’s Emergency Plan for AIDS Relief (PEPFAR) on all cause mortality in 12
focus countries. The authors find that after introduction of PEPFAR (2004-2008) the odds ratio of
all cause mortality in focus countries was 0.84 compared with non focus countries. Another study,
and one that is closer in objective to ours is by Nunnenkamp and Ohler (2011). The authors use
estimates from UNAIDS on AIDS related mortality and a constructed measure of new infections to
study the impact of foreign aid (for HIV) commitments. The authors use a difference-in-differences
approach and compare high prevalence countries that received more foreign aid (intervention) with
those that received less (control). They find no statistically significant effect of aid on new infections
of HIV. In the case of mortality, they find no overall effect, but reductions from aid given by bilateral
donors only.
In contrast, our paper provides empirical evidence that foreign aid for HIV has reduced new
infections of HIV and we do this by improving upon their empirical strategy in several ways. First,
we recognize the endogenous properties of aid allocations. There is extensive literature particularly
focusing on aid and economic growth , or aid and conflict (de Ree and Nillesen, 2009; Tavares, 2003;
Collier and Hoeﬄer, 1998) that have highlighted the importance of controlling for the endogeneity
of foreign aid. In our case, several time varying unobservable factors may influence the amount of
aid a country receives, in addition donors my predict or anticipate changes in the number of new
infections and adjust aid flows accordingly. Estimates of aid flows that do not account for this
endogeneity will combine the causal impact from aid to new infections with correlations caused
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by endogeneity. We use a strong instrument based on GDP per capita of international donors to
separate and recover the casual effect. Second, rather than construct a variable of new infections
as the difference between prevalence and mortality as done by Nunnenkamp and Ohler (2011) we
use published UNAIDS estimates. These estimates are the most reliable source of information on
new infections and are widely used to measure the state of the epidemic. Third, we look at a longer
time frame as compared to the previous studies. Our data covers 1995 -2011. As far as we are
aware this paper is the first to use an instrumental variables approach to recover the causal effect
of foreign aid for HIV on new infections.
In Section 2 we discuss our empirical strategy and detail our identification strategy. Section 3
describes our data, its sources and presents stylized facts. In Section 4 we present our regression
outcomes and discuss our results along with findings from several robustness checks. Section 5
concludes.
2 The empirical analysis of new HIV infections
The objective of this paper is to identify and to estimate the causal effects of aid flows on new
infections of HIV in low middle income countries. Using non-experimental data to identify causal
effects requires certain identifying restrictions. For example, Nunnenkamp and Ohler (2011) use a
difference-in-differences approach. Their approach relies on a “parallel trend” assumption which
requires that the time effect is common to both treatment and control groups and any group effects
are driven by “time-invariant” differences (observable or unobservable). In studying the relationship
between aid and new infections, there are two problems with this approach. The first, is that
countries in their selected treatment and control groups are unlikely to have a parallel trend. The
authors find this is the case and that the outcome variable (mortality or new infections) is correlated
with the dynamic of the epidemic. In addition, Nunnenkamp and Ohler (2011) assume that aid
allocation is exogenous with respect to future levels of new infections. We argue that ignoring this
issue could potentially bias their estimates and may explain why they find no correlation between
aid and new infections.
This paper focuses on two key aspects to recovering reliable causal estimates. Time invariant
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effects: such as gender equality, governance, cultural and social beliefs or other partly unobserved
factors (de Ree and Nillesen, 2009) are likely to determine the extent of new infections. These factors
are also likely to be correlated to the extent of aid that countries receive. In fact Nunnenkamp
and Ohler (2011) illustrate that despite their sample countries all having being classified as having
an HIV prevalence over 1%, the amount of aid received differed greatly amongst these countries.
They use this fact to divide their sample into treatment and control groups. To address this issue
we include a country-specific effect that captures time-invariant unobservables that are potentially
correlated with HIV aid flows and new infections in a country. If such a specification captured
all potential sources of endogeneity then such a fixed-effects specification would suffice to recover
causal effects.
Endogeneity in aid allocation: There could be two causes of endogeneity, firstly - time-varying
unobservables not captured by fixed-effects such as failing health systems or governments, antici-
pated shifts in other disease burdens or the potential for conflict in the countries are likely to be
correlated with aid-flows for HIV (omitted-variable bias) and are potentially likely to influence new
HIV infections. Secondly, reverse causality. Our concern in this case is that it difficult to perceive
aid allocations as being independent of the level of new infections in the recipient country. We thus
adopt an instrumental variables (IV) approach to address the endogeniety issue.
Our instrumental variables model with country-specific effects is specified below, where infit
represents new HIV infections in country i at time t. New infections depend on aidit - the amount
of aid received and a vector Xit containing covariates that potentially influence both the outcome
(new infections) and the amount of aid received. The model can be written as:
infit = βaidit + δXit + αi + it (1)
where αi is a country-specific effect that captures the above mentioned time invariant effects that
are likely to be correlated with both HIV aid allocations and new infections in a specific country.
it represents a random, idiosyncratic error term. The above model when estimated using a fixed-
effects approach to eliminate correlations between βaidit , δXit and αi will yield unbiased and
consistent estimates of the parameters of interest under the following assumption:
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E[it|αi, aidit, Xit] = 0 (2)
However we have argued that the endogeneity of aid flows is driven not only by correlations with
the fixed effects but also by other time varying omitted variables and potential reverse causality.
In the presence of potential endogeneity of aidit the above will lead to biased estimates of the β
coefficients.
To recover unbiased and consistent estimates an IV estimator requires that we identify one or
more “instrumental” variables Zit that create exogenous sources of variation in the endogenous aid
variable aidit. Specifically, a suitable instrument must have the following properties, with all other
relevant variables controlled for, the instrument should be:
1. correlated with changes in the endogenous variable (aidit) but should not lead to changes in
new infections (except indirectly via aidit) ie. good first stage explanatory power
2. uncorrelated with the error term of the regression model specified in equation (1) ie the
exclusion restriction must not be violated:
E[it|αi, Zit, Xit] = 0 (3)
If the instruments have the above properties, we should be able to recover unbiased estimates
(of β) of the effect of HIV aid allocations on new infections from equation (1) using two-stage least
squares (IV-2SLS) (Cameron and Trivedi, 2005).
We follow the literature on aid-effectiveness in selecting our instrument (de Ree and Nillesen,
2009; Tavares, 2003; Collier and Hoeﬄer, 1998). We use GDP per capita of large western donor
countries as an instrument for HIV aid flows. The rationale for this selection is based on the idea
that aid flows to low middle income countries are linear functions of donor GDP where donor
contributions are generally in proportion to their country income levels. The 2001 United Nations
General Assembly Special Session (UNGASS) in their “Declaration of commitment on HIV/AIDS”
reaffirmed their resolution (2626) that donor countries would contribute 0.7% of gross national
6
product (GNP) for overall overseas development assistance (ODA) with about 0.15% to 0.20%
GNP aimed at least developed countries (Assembly, 2001). In particular reaffirming that those
countries that had failed to thus far achieve this target would aim to do so. Although only a few
countries have achieved this target, generally ODA commitments tend to be a specific fraction
of GDP levels irrespective of the instabilities or potential conflicts within the recipient countries.
Disbursements of ODA to countries are however often dependent on the strategic interests of donors
(Lane and Glassman, 2007), political situation of the recipient country and other often unobservable
factors, thus making aid flows endogenous.
We use GDP per capita of the USA as our instrument. The US government remains the largest
donor to HIV efforts, with disbursements accounting for almost 64% of all contributions from donor
governments. Good first stage explanatory power as described in property (1) above means that
donor GDP per capita is partially correlated with our aid variable (after controlling for other factors
affecting new infections). This means that variations in GDP per capita will induce variations in the
amount of aid disbursed across countries and within countries over time. This exogenous variation
in the amount of aid will in turn lead to changes in the number of new infections. It is reasonable to
assume that changes in the number of new HIV infections in a country as a response to variations in
GDP per capita of donors is channeled solely through the amount of HIV aid received by a country
ie, property (2) holds. But in order to control for any potential indirect effects of donor GDP on
the number of new HIV infections, in all the models we control for GDP per capita of the recipient
country and public health expenditure as a share of total health expenditure. By including public
health expenditure we also control for the effect of domestic spending on new infections. We also
provide results of specification tests. Finally, to assess the relevance of our instrument we present
F-tests of its significance in the IV regressions as well as results from underidentification tests
(Angrist and Pischke, 2009).
The omitted variables that cause endogeneity problems in the fixed-effects least squares setting
also limits are choice of instruments. Often instruments are chosen that represent specific charac-
teristics of recipient countries that are correlated with aid disbursements. However, these country
characteristics are also likely to be correlated with our outcome variable - new HIV infections.
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Hence we choose not to interact our instrument with any country specific characteristics as done
by Tavares (2003); Collier and Hoeﬄer (1998). For example cultural proxies, geographical distance
or common language could be interacted with the US GDP per capita to give us a country specific
instrument. However, we feel that geographical positioning, language or cultural factors are likely
to be correlated with new infections and interacting them with US GDP per capita will give us a
less reliable instrument. For example, Oster (2012) uses geographical positioning as an instrument
for HIV prevalence by measuring distance of a country to the origin of the HIV epidemic.
Using US GDP per capita provides us with a strong instrument, but comes with a limitation
in that because it does not vary by country we are unable to include time dummies for all years
in the models. This would present a problem if for example a time shock was correlated with US
GDP that also influences new HIV infections. As mentioned earlier, we include GDP per capita
for each country in our model along with public health expenditure (as a share of total health
expenditure). We would expect these variables to be able to capture most of these effects. But, we
also include other variables such as HIV prevalence, the occurrence of conflict and political status
to capture any additional effects not captured by GDP per capita or health expenditure as well as
population structure to capture cross country differences. In addition, in our robustness checks we
also allow for GDP growth and the number of refugees in a country. We also estimate models with
time dummies for years that have witnessed global shocks.
3 Data Description
3.1 Data and Variables
Our estimation sample focuses on low income and low middle income countries as defined by
the World Bank classification and covers the years 1995 to 2011. In total there are 82 countries in
our sample for which we have estimates of new infections. Table 1 presents descriptive statistics of
all the variables.
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Table 1: Summary statistics - Low income and low middle income countries
Variable Mean Standard
deviation
Minimum Maximum
Ouctomes
New infections - all age groups 33011.1 63301.74 100 360000
New infections - adults 26526.47 52602.79 100 350000
New infections - children 6185.13 12465.46 100 66000
Regressors
Aid disbursements per capita 1.13 3.24 0 50.59
Polity2 index 1.45 5.77 -10 10
Conflict 0.22 0.42 0 1
HIV prevalence - adults (%) 2.69 5.01 0.1 28.7
Health expenditure, public (% of total
health expenditure)
43.20 17.41 3.32 86.24
GDP per capita 979.04 853.54 50.04 4690.94
% Population 0 to 14 39.01 7.90 13.87 50.74
% Population 15 to 64 56.70 6.07 45.99 73.50
US GDP per capita 38936.38 7056.659 27776.43 48407.08
The time period is 1995 -2011
3.1.1 Outcome variable - new HIV infections
Our main variable for analysis is the number of new HIV infections. We use data on the annual
number of new HIV infections (adults and children) estimated by UNAIDS. These data are available
at the country level for the years 1990 to 2013. In addition, data are available by sub-groups -
adults 15 years and older and children 0-14 years newly infected with HIV. For some countries,
for years with very few new infections (estimate < 100), the number is rounded off to 100. These
data are are widely used as progress measures of the fight against the HIV epidemic and presented
annually in UNAIDS’ report on the epidemic (UNAIDS, 2013b). We use all three variables and
conduct analysis on the overall number of infections and on sub-groups.
3.1.2 Foreign aid for HIV
The primary explanatory variable of interest is foreign aid for HIV measured as development
assistance for health (DAH) allocable to all programs relating to HIV/AIDS. These data are taken
from the development assistance for health database developed by the Institute for Health Metrics
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and Evaluation (IHME, 2009). The DAH database provides annual country level data on dis-
bursements of HIV specific aid by key funding agencies. Data are available from 1995 - 2011. We
calculate the foreign aid variable as HIV specific DAH flows to a country relative to its population
(per capita) lagged one period (t-1). The variable is measured in US$. In all cases we construct
log’s of our foreign aid variable, thus the effect of a percentage change in foreign aid on the number
of new infections can be estimated directly.
3.1.3 Instrument and other variables
As discussed in the methodology section we use US GDP per capita as an instrument to address
the endogeneity of the aid variable . We use GDP per capita data taken from the World Bank’s
World Development Indicators (WDI) database. Similar to our endogenous variable, the instru-
ment is also lagged one period (t-1). In addition, to control potential indirect effects of foreign
aid we include GDP per capita (t-1) of recipient countries, public health expenditure as a share
of total health expenditure (t-1) and population structure (t-1). These data are taken from the
WDI database and the WHO Global Health Observatory database. Several studies Brckner (2013);
Alesina and Dollar (2000); Trumbull and Wall (1994) have highlighted the importance of political
institutions and civil war on donor contributions of aid. For these two factors to be omitted vari-
ables, it must be the case that annual within-country changes in political institutions or occurrence
of conflicts must lead to an immediate effect on the number of new infections. We include two
variables in our model, the first a dummy variable for conflict (lagged one period, t-1) which takes
the value 1 if armed conflict occurred in the recipient country in a specific year. These data are take
from the PRIO/UPSALLA database on armed conflicts. This data set has been widely used since
it was made available (Gleditsch et al., 2002). Our second variable represents the political set-up
within a country. The variable (lagged one period, t-1) ranges from -10 to +10 (democratic) and
is taken from the Polity IV database. In addition, we include lagged (t-1) HIV prevalence in each
country taken from UNAIDS estimates to control for the extent of the epidemic with a country.This
setup represents our main specification and results. We then carry out a series of robustness checks
described later in the paper.
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3.2 Stylized Facts
We first examine some basic correlations between new infections and foreign aid for HIV. Figure
1 summarizes the correlation between cross-country averages of the log of aid per capita and the
number of new infections for all age groups. The data is constructed by averaging each variable
over the sample time frame. The observations are labeled using their World Bank country codes.
For brevity we do not present graphs for our two other outcome variables - new infections amongst
adults and new infections amongst children, as our conclusions are the same.
(a) Aid and new HIV infections - LMICs
(b) Aid and new HIV infections - excluding lowest tercile of aid
Figure 1: Between country correlations between aid and new HIV infections
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Figure 1(a) reveals no clear direction in the relationship between aid per capita and new in-
fections. This lack of relationship is also reflected in the correlation coefficient which is very low
(0.03) and statistically insignificant. In figure 1(b) we exclude countries that received low amounts
of aid for HIV by constructing a variable that represents terciles of aid received, where the lowest
tercile includes countries with the least increase in the amount of aid received and the top tercile
includes countries with the greatest increase in aid over our sample period. Excluding countries in
the lowest tercile still yields a very low correlation coefficient (0.05) which is also not statistically
significant. This lack of correlation may reflect the complex relationship between foreign aid for
HIV and new infections. Aid allocation mechanisms and new infections are influenced by a range
of factors, many of which are unobservable - such as social, cultural and epidemiological factors.
Ignoring these unobservable influences can cause bias in our estimates, particularly those that affect
both aid allocations and new infections of HIV.
Figure 2 presents the correlation between number of new infections and aid over time, in this
case our focus is to identify aggregate time series variation. We present graphs for all three outcome
variables. The correlations are again presented by terciles of aid received. We focus on the top and
bottom terciles for brevity.
In the case of new infections across all age groups (figure 2(a)) we see a clear negative relationship
with aid in both the upper and lower terciles. However, these unadjusted correlations show no clear
direction in the case of new infections in children(2(b)), where in the top tercile we see a rise in
the number of new infections followed by a downward trend. In the case of adults, countries in the
top tercile of increase in HIV aid per capita exhibit a clear reduction in adult new infections over
time, while countries in the bottom tercile also show reductions but primarily after 1997. Thus
we observe a fair amount of aggregate time series variation in the relationship between aid and
new infections of HIV. The top tercile in general consists of most of the “HIV focus” countries
of sub-Saharan Africa which clearly start the sample with much higher levels of new infections,
indicating that aid has been channeled in most cases to countries with large disease burdens. These
raw correlations suggest that the returns to an additional dollar being spent (especially in high
prevalence countries) could potentially yield higher marginal returns.
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(a) New infections - all age groups
(b) New infections - children
(c) New infections - adults
Figure 2: Average new HIV infections over time across groups (terciles) of countries with the largest
and smallest increases in aid. (- -, top tercile; — —, bottom tercile).
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Thus far we have observed little correlation from cross-country variations and some from aggre-
gate time-series variation. Finally, before we move on to our main estimates we look for evidence
of within-country correlations overtime. Figure 3 shows that within countries, more aid per capita
is associated with fewer new infections in the case of adults and across age groups. In the case of
children no clear direction is visible. These correlations are generally difficult to interpret as they
do not control for any observable factors and only remove the country and time specific effects.
In general the mixed outcomes from the raw correlations shows the complex nature of the
relationship between aid and new infections and the potential risks associated with assuming a lack
of causality due to lack of variation. In section 4 we present estimates of our models that address
the concerns raised with these raw correlations and provide evidence of the robustness of our main
results.
4 Results
4.1 The causal effect of aid on new HIV infections
We use the instrumental variables approach outlined in section 2 to recover credible estimates
of the impact of foreign aid on new infections. In tables 2 and 3 we present our main results for
all three models -“all age groups”, “adults” and “children”. Before we begin our discussion of
the results we analyse the performance of our instrument. First, we return to our methodology
section where we suggested that a potential reason why Nunnenkamp and Ohler (2011) find no
statistically significant effects could be because they fail to account for the endogeneity of the aid
variable. In table 2 we present first stage estimates of our IV-2SLS models that link the instrument
(US GDP per capita) to the endogenous variable (foriegn aid per capita). All three models show
the instrument is statistically significant at least at the 1%. The point estimate is positive as we
would expect and shows that aid disbursements increase with US GDP per capita. The table also
presents results from the Lagrange Multiplier (LM) test for underidentification (Kleibergen and
Paap, 2006). The results strongly reject underidentification in the first stage IV estimations. The
instrument also yields large first-stage F-statistic indicating that bias due to weak instruments is
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(a) Within country correlations - new infections - all
age groups
(b) Within country correlations - new infections - chil-
dren
(c) Within country correlations - new infections - adults
Figure 3: Within-country correlations are identified by regressing both aid per capita and new
infections on a set of country and time dummies. The residuals from both regressions are plotted
against each other
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unlikely to be a problem in our model and there is good first stage explanatory power (property 1
discussed earlier). This means that donor’s GDP is partially correlated with our measure of foreign
aid (after controlling for other factors that might influence new infections).
Table 2: First stage estimates - Effect of US GDP per capita on foreign aid for HIV
All age
groups
Adults Children
1 2 3
IV- 2SLS IV- 2SLS IV-2SLS
Dependent variable: Log per capita foreign aid for HIV (t-1)
US GDP per capita (t-1) 0.0002*** 0.0002*** 0.0002***
(0.000) (0.000) (0.000)
Controls Yes Yes Yes
Underid (LM test) p-val 0.000 0.000 0.000
First-stage F-stat 109.57 109.57 96.80
Observations 881 881 904
The method of estimation is two-stage least squares.
Regressions control for GDP per capita, public health exp (% of total health expenditure), conflict,
polity2, share of population 0-14 years and 16 -64. Models include country fixed effects.
Robust standard errors clustered at the country level presented in parentheses.
* indicate significant difference from zero at *90% confidence, **95% confidence and *** 99% confidence
In table 3 we present two sets of results - a fixed-effects specification (FE-LS) and corresponding
IV estimation (IV-2SLS). Columns (1) and (2) report results for the effect of aid on new infections
across all age groups. Columns (3) and (4) for adults, (5) and (6) for children. In all models our
foreign aid variable is in log form. This enables us to interpret a percentage change in aid per
capita as a change in the number of new infections.
We begin our discussion of the results with the model in column (2) of table 3. The IV
estimations strongly indicate that higher levels of aid disbursements per capita lead to lower number
of new infections. The point estimate is statistically significant at the 5% level and shows that a
1% increase in aid disbursed per capita to a low-middle income country results in 4849 fewer new
infections. The corresponding fixed-effects estimates presented in column (1) shows much smaller
statistically significant effect of aid on reduced new infections. Using an IV estimator to control
for endogeneity of the aid variable leads to a larger, negative, statistically significant effect. These
results indicate an overall effect of aid on new HIV infections. This result can be corroborated
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Table 3: The effect of foreign aid on new infections of HIV
All age groups Adults Children
1 2 3 4 5 6
FE-LS IV-2SLS FE - LS IV-2SLS FE - LS IV-2SLS
Aid disbursements per capita
(t-1) (log)
-2327** -4849** -2080** -4411** -221 -365
(1079.35) (2207.38) (972.82) (2041.26) (200.13) (401.61)
Polity2 (t-1) 654 882 547 758 97 110
(615.27) (627.69) (526.53) (529.72) (145.17) (142.79)
Conflict (t-1) 2515 2882 2231 2570 188 215
(5660.41) (5533.61) (5446.59) (5320.34) (369.79) (355.95)
HIV prevalence - adults (t-
1)(%)
3952** 4175** 2266* 2473* 1687** 1706**
(1820.54) (1805.47) (1306.45) (1342.12) (673.54) (668.29)
Health expenditure, public (t-
1) (% of total health expendi-
ture)
-348 -187 -309 -160 -41* -32
(216.47) (239.25) (207.90) (234.58) (22.74) (24.60)
GDP per capita (t-1) 2 1 0 -0 1 1
(5.04) (5.64) (5.43) (5.81) (1.03) (1.09)
% Population 0 to 14 (t-1) 3198 4452 3093 4252 76 101
(3329.86) (3645.01) (3250.07) (3481.98) (493.61) (507.40)
% Population 15 to 64 (t-1) 2859 4888 2933 4808 -76 -10
(3346.28) (3877.49) (3181.32) (3626.46) (549.45) (562.15)
Constant -257014 -258522 2822
(321291.15) (309820.20) (50255.31)
Underid (LM test) p-val 0.000 0.000 0.000
First-stage F-stat 109.57 109.57 96.80
Observations 881 881 881 881 904 904
All models include country fixed effects. Robust standard errors clustered at the country level presented in parentheses.
* indicate significant difference from zero at *90% confidence; **95% confidence and *** 99% confidence
by recent reports from UNAIDS (UNAIDS, 2013a) which have found that by 2012 there was 33%
reduction in new infections amongst adults and children when compared with 2001.
Over the last decade prevention programs have focused on many different kinds of interventions.
For adults, these have included behaviour change interventions, medical male circumcision, focus
on high-risk groups such as injecting drug users, sex-workers and men-who-have-sex with men.
But HIV is also a leading cause of death amongst women of reproductive age worldwide and a
major cause of infant mortality. Mother-to-child transmission (MTCT) is when an HIV - positive
mother passes the virus to her child during pregnancy, labour, delivery or breast-feeding. Since
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2001 when the UN member states made a global commitment to the prevention of mother-to-child
transmission (PMTCT), it has become a major focus area in the fight against the HIV epidemic.
Therefore in addition to our model for combined age groups and adults, we also run a separate
model to identify whether foreign aid has had an impact in reducing new infections in adults and
children.
In columns (3) and (4) we present the impact on new infections amongst adults. The IV
estimates are striking and show that foreign aid has a clear negative effect on new infections amongst
adults. The estimate is statistically significant at the 5% level and shows that a 1% increase in per
capita foreign aid reduces new infections in adults by about 4411. These impressive results are also
reflected in the UNAIDS World AIDS Report (UNAIDS, 2012) which highlights that more than
25 LMICs achieved atleast a 50% reduction in the new infections amongst adults between 2001
and 2011. As expected the fixed-effects specification shows a small negative impact. In column (6)
we present results for new HIV infections amongst children. In this case however, while we see a
negative association between foreign aid and new infections, our result is not statistically significant.
This result seems rather unusual to us given that many countries have declared successfully reducing
new infections in children. We believe there are two possible reasons for the results we see. First, it
is possible that these results are masking differential effects for regions such as sub-Saharan Africa,
a region that has the most number of HIV positive children and receives a large proportion of aid.
For example, of all newly infected children in 2011, more than 90% live in sub-Saharan Africa.
We return to the question of differential effects in our section of robustness checks and investigate
further. Second, recent reports from UNAIDS mention that most of the reductions amongst children
have taken place in the last two years of our sample (2009-2011)(UNAIDS, 2012). In general we
conclude that across all LMICs there have been significant reductions in new infections amongst
adults but not amongst children.
4.2 Specification and robustness checks
In this section we undertake a series of specification and robustness checks to verify that the
results we observe above are reliable estimates of the causal effect of foreign aid on new infections
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of HIV.
4.2.1 Robustness to specification
Table 4: Effect of aid on new infections - including additional controls and time effects
All age groups Adults Children
1 2 3 4 5 6
IV-2SLS IV-2SLS IV-2SLS IV-2SLS IV-2SLS IV-2SLS
Aid disbursements per
capita (t-1) (log)
-4938** -5070** -4546** -4637** -307 -387
(2354.12) (2361.01) (2184.31) (2189.20) (371.99) (433.61)
Additional variables Yes Yes Yes
Time dummies Yes Yes Yes
Underid (LM test) p-val 0.000 0.000 0.000 0.000 0.000 0.000
First-stage F-stat 117.91 96.17 117.91 96.17 109.72 94.33
Observations 838 881 838 881 861 904
The method of estimation is two-stage least squares. Columns (1), (3) and (5) include GDP growth rate and number of refugees
Columns (2), (4) and (6) include time dummies for years 2000-2003 and 2007-2010.
Regressions control for GDP per capita, public health exp (% of total health expenditure), conflict,
polity2, share of population 0-14 years and 16 -64. Models include country fixed effects.
Robust standard errors clustered at the country level presented in parentheses.
* indicate significant difference from zero at *90% confidence, **95% confidence and *** 99% confidence
We described in our methodology section that while we have a strong instrument, it has limita-
tions in that we are unable to include time dummies for all years to capture shocks to the number
of new infections. Instead we have included several variables we believe will capture any indirect
effects of US GDP per capita on new infections of HIV. In this section we provide two alternate
specifications. First, we include two further variables - growth rate of GDP in each country and
the number of refugees in a country. We expect these variables to capture the influence of external
economic influences as well as any regional uncertainty leading to migration. Second, we include
time dummies for years in which there were global shocks such as recessions or global financial crises
2000 − 2003 and 2007 − 2010. In addition, the 2000-2003 dummies will also capture any shocks
from the setting up of the Global Fund for AIDS, TB and Malaria (GF) and The US President’s
Emergency Plan for Aids Relief (PEPFAR). Table 4 presents these results. Columns (1) , (3) and
(5) include the additional variables mentioned above and columns (2) , (4) and (6) include time
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dummies. In both sets of specifications the results are similar to our main findings in table 3 in
terms of magnitude as well as statistical significance. We also estimate the models with time dum-
mies for the years 2000-2010. These results are very similar to our baseline estimates and hence we
do not present them.
4.2.2 Allowing for differential effects in sub-Saharan Africa
Table 5: Effect of aid on new infections - differential effects in sub-Saharan Africa
All age
groups
Adults Children
1 2 3
IV- 2SLS IV- 2SLS IV-2SLS
Baseline estimates
Aid disbursements per capita
(t-1) (log)
-4849** -4411** -365
(2207.38) (2041.26) (401.61)
Sum of coefficients of main effect and interaction term
Aid disbursements per capita
(t-1) (log)
-4441 -3611 -604**
(971.26) (936.73) (118.28)
Underid (LM test) p-val 0.000 0.000 0.000
First-stage F-stat 93.90 93.90 58.40
Observations 881 881 904
The method of estimation is two-stage least squares.
Regressions control for GDP per capita, public health exp (% of total health expenditure), conflict,
polity2, share of population 0-14 years and 16 -64. Models include country fixed effects.
Robust standard errors clustered at the country level presented in parentheses.
* indicate significant difference from zero at *90% confidence, **95% confidence and *** 99% confidence
The raw correlations examined in section 2 indicate that aid was primarily targeted at countries
with high initial levels of new infections. This is particularly the case for HIV where sub-Saharan
Africa has the greatest disease burden. The majority of these countries are also low-income coun-
tries. It is thus possible that high-prevalence countries in sub-Saharan Africa (SSA) may have
experienced different results to aid flows when compared to other regions. Our specifications have
included country-specific effects which should capture the impact of initial levels of new infections
that may confound our results. In addition, the time varying variables we include and the use of
an instrument should account for any unobservables that are likely to confound our results. Also
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as discussed earlier in our results for the model for children, we suspect that the reason we see no
statistically significant results across all LMICs is because differential effects are being masked. In
this section we explore further if the returns to international aid is different in sub-Saharan Africa
- countries that are mainly low income but also high prevalence, we allow for differential effects in
our model by adding an interaction term between the foreign aid variable and a dummy variable
representing SSA (=1). We use our full sample of LMICs and IV-2SLS where our instrument for
the interaction term is the interaction between US GDP per capita and SSA. Table 5 presents these
results. The coefficients presented are the sum of the aid variable (main effect) and the respective
interaction term which gives the total estimated effect of aid disbursements on new infections of
HIV for SSA. The first and second columns of table 5 shows no statistically significant differential
effects for our model for all age groups and adults. In column (3) we present our estimate for the
model for children. Unsurprisingly we find a clear statistically significant reduction in new infec-
tions with a 1% increase in foreign aid resulting in almost 600 fewer infections amongst children
in SSA. The magnitude of our coefficient is more than 1.5 times larger than our estimate for all
LMICs. These results indicate that our findings for children in table 3 were indeed masking regional
differences.
4.2.3 Further checks: other variables as instruments and excluding outliers
In this section we conduct two further tests of robustness. Our first robustness check uses GDP
per capita of other large donors such as the United Kingdom (UK), Japan, France or Germany as
an instrument for aid flows instead of US GDP per capita. Our results are similar irrespective of
which country we substitute for the USA as our IV. For brevity we do not present these results
here. However, in table 6 we present results of a model where we include the GDP per capita
of France in addition to US GDP per capita as instruments. Our results remain the same if we
substitute Germany instead of France. However we find that GDP per capita of UK or Japan - do
not work well when included in addition to US GDP per capita. Their strong correlation with US
GDP per capita eliminates their relevance in the first stage results. We therefore present results
including France (the results for Germany are similar). Including the additional instrument allows
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Table 6: Effect of aid on new infections - other specification and robustness checks
All Adults Children
1 2 3
IV- 2SLS IV- 2SLS IV- 2SLS
Baseline estimates
Aid disbursements per capita
(t-1) (log)
-4849** -4411** -365
(2207.38) (2041.26) (401.61)
Including GDP per capita of France as additional IV
Aid disbursements per capita
(t-1) (log)
-4437** -3937** -428
(1960.36) (1800.57) (374.89)
Underid (LM test) p-val 0.000 0.000 0.000
First-stage F-stat 72.09 72.09 63.08
Hansen J-Statistic p-value 0.20 0.14 0.21
Observations 881 881 904
Excluding outliers
Aid disbursements per capita
(t-1) (log)
-4901** -4464** -363
(2240.19) (2072.41) (402.53)
Underid (LM test) p-val 0.000 0.000 0.000
First-stage F-stat 105.91 105.91 96.02
Observations 877 877 898
The method of estimation is two-stage least squares.
Regressions control for GDP per capita, public health exp (% of total health expenditure), conflict,
polity2, share of population 0-14 years and 16 -64. Models include country fixed effects.
Robust standard errors clustered at the country level presented in parentheses.
* indicate significant difference from zero at *90% confidence, **95% confidence and *** 99% confidence
us to carry out tests for over-identification. This test refers to our second property for a valid
instrument - ie. that it must be uncorrelated with the error term. The Hansen J-statistic p-values
indicate our instruments are not likely to be correlated with the error term. The LM statistics
and the first stage F-statistics indicate that weak identification is not a problem in our model.
Overall, our results continue to show a statistically significant negative impact of foreign aid on
new infections for our combined model and amongst adults, once again in the case of children we
find no significant impact.
Our second test eliminates outliers that might be driving our main results in table 3. We use a
formal statistical procedure for the elimination of outliers in multivariate cases (Weber, 2010). We
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exclude outliers for both the foreign aid variable and each of our dependent variables. We eliminate
6 country-year observations that are identified as being outliers in our model across age groups
(Lesotho 2011, Swaziland 2006-2011 and Zambia 2009). For our model of adults and children we
eliminate Guyana 2007-2010 and Swaziland 2011. We estimate our IV models again excluding these
observations. The results are presented in the third part of table 6. Once again we find that are
results are close to the baseline estimates.
5 Conclusion
Our analysis shows that once we control for the endogeneity of foreign aid, it has a negative
impact (reduction) on the number of new infections. The results show that increasing foreign aid
for HIV results in a statistically significant decrease in the number of new infections amongst adults
in LMICs. We do not however find such an effect amongst children. Further checks reveal that in
the case of children there is a reduction once we allow for differential effects in sub-Saharan Africa,
these effects are statistically significant. In terms of magnitude our results are also economically
relevant with a marginal effect of -4411 fewer HIV infections amongst adults across LMICs and
-604 amongst children in SSA. In our sample a 1% increase in foreign aid is on average equivalent
to around $161,000 in the case of LMICs and $243,000 in SSA.
Through this study we add to the literature in several ways. As far as we know this is the first
paper to explicitly account for the endogeneity of foreign aid (for HIV) in studying its impact on new
infections of HIV. In fact it is one of the few papers to focus on this crucial indicator. Earlier studies
have either ignored the endogeneity issue, used a roughly constructed measure of new infections
or not focused on our outcome. We are also able to study the effects separately for adults and
children. We eliminate any correlation with time-invariant unobservables through a fixed effects
specification and use donor GDP as a powerful instrument to recover causal estimates. The other
study that also considers the same question as us is that of Nunnenkamp and Ohler (2011) who find
negative coefficients in their various specifications but none of which are statistically significant.
Given this result the majority of their paper focuses on mortality as an outcome. We are thus
able to provide crucial evidence on the effectiveness of aid for HIV in controlling the spread of the
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epidemic, a question that is particularly relevant given the calls to increase the amount of funding
channeled to the disease and concerns of displacement of other diseases. Our results are reassuring
in that the vast of amounts of aid channeled towards the treatment, prevention and control of HIV
do not seem to have been entirely misplaced.
Our study however has some limitations. The epidemiological and medical literature on HIV has
recently shifted focus from behavior change and prevention programs to the idea of “treatment as
prevention” (Cohen et al., 2011), recognizing that recent medical developments mean HIV positive
individuals who adhere to their treatment are virally suppressed and therefore less likely to infect
other individuals. An important question is whether the reductions we see are channeled through
investments in prevention and behavior change programs or through increases in treatment. We are
unable to shed light on this question as we lack data on foreign aid expenditure categories. As WHO
extends its treatment threshold and more individuals become eligible for treatment, future research
into the channels through which foreign aid influences new infections will become more relevant.
This crucially also depends on how transparent donors are in their aid allocation decisions and the
extent to which data on expenditure categories is made available. However, there still remains the
larger question of whether disease specific “vertical” programs are the most appropriate methods
of allocating development assistance for health. Recent years have seen a gradual shift towards
more horizontal approaches to health care financing with health system strengthening becoming
a core component of aid allocations which will hopefully limit displacement of funding from other
diseases.
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